期刊名：Antibodies

期刊主页：https://www.mdpi.com/journal/antibodies

单克隆抗体是一类由单一B细胞克隆产生的高度均一的抗体，广泛应用于癌症治疗、自身免疫性疾病、感染性疾病以及诊断检测等多个领域，本期精选15篇单克隆抗体领域文献，希望能为相关领域学者提供新的思路和参考，欢迎阅读。

1. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

皮肤T细胞淋巴瘤CCR4疗法现状叙述性回顾：重点关注Mogamulizumab及未来疗法

https://www.mdpi.com/2073-4468/13/2/32

Zengarini, C.; Guglielmo, A.; Mussi, M.; Motta, G.; Agostinelli, C.; Sabattini, E.; Piraccini, B.M.; Pileri, A. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments. Antibodies 2024, 13, 32.

2. Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data

与阿替利珠单抗相关的免疫相关不良事件：来自真实世界药物警戒数据的见解

https://www.mdpi.com/2073-4468/13/3/56

Frey, C.; Etminan, M. Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data. Antibodies 2024, 13, 56.

3. Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab

CAR-CD19修饰或可溶性双特异性抗体Blinatumomab增强细胞因子诱导杀伤细胞的功能活性

https://www.mdpi.com/2073-4468/13/3/71

Zaninelli, S.; Panna, S.; Tettamanti, S.; Melita, G.; Doni, A.; D’Autilia, F.; Valgardsdottir, R.; Gotti, E.; Rambaldi, A.; Golay, J.; et al. Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab. Antibodies 2024, 13, 71.

4. A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)

针对胰腺导管腺癌靶点前梯度-2（AGR2/PDIA17）的高亲和力单克隆抗体

https://www.mdpi.com/2073-4468/13/4/101

Robinson, R.M.; Reyes, L.; Christopher, B.N.; Duncan, R.M.; Burge, R.A.; Siegel, J.; Nasarre, P.; Wang, P.; O’Bryan, J.P.; Hobbs, G.A.; et al. A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Antibodies 2024, 13, 101.

5. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling

使用基于群体生理学的药代动力学模型表征单克隆抗体临床药代动力学中的抗体间变异性

https://www.mdpi.com/2073-4468/13/3/54

Kumar, M.; Lanke, S.; Yadav, A.; Ette, M.; Mager, D.E.; Shah, D.K. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling. Antibodies 2024, 13, 54.

6. Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays

通过浓度和抗药抗体评估对英夫利昔单抗和阿达木单抗进行治疗药物监测；Sanquin Diagnostics 与 Theradiag 检测方法的比较

https://www.mdpi.com/2073-4468/13/3/73

Vroemen, W.H.M.; Agata, S.S.; van Beers, J.J.B.C.; Damoiseaux, J.G.M.C. Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays. Antibodies 2024, 13, 73.

7. Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas

开发新型抗CD44变体5单克隆抗体C44Mab-3用于多种治疗胰腺癌的应用

https://www.mdpi.com/2073-4468/12/2/31

Kudo, Y.; Suzuki, H.; Tanaka, T.; Kaneko, M.K.; Kato, Y. Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas. Antibodies 2023, 12, 31.

8. Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy

扩大单克隆抗体的覆盖范围：免疫疗法中合成核酸递送的综述

https://www.mdpi.com/2073-4468/12/3/46

Chung, C.; Kudchodkar, S.B.; Chung, C.N.; Park, Y.K.; Xu, Z.; Pardi, N.; Abdel-Mohsen, M.; Muthumani, K. Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy. Antibodies 2023, 12, 46.

9. Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies

减毒免疫作为开发呼吸道合胞病毒（RSV）特异性单克隆抗体的方法

https://www.mdpi.com/2073-4468/12/4/62

Jacobs, L.; Stobbelaar, K.; Heykers, A.; Cos, P.; Delputte, P. Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies. Antibodies 2023, 12, 62.

10. Novel Monoclonal Antibody Specific toward Amyloid-β Binds to a Unique Epitope within the N-Terminal Region

针对淀粉样β蛋白的新型单克隆抗体与N端区域内的独特表位结合

https://www.mdpi.com/2073-4468/13/3/68

Paterno, G.; Moore, B.D.; Bell, B.M.; Gorion, K.-M.M.; Ran, Y.; Prokop, S.; Golde, T.E.; Giasson, B.I. Novel Monoclonal Antibody Specific toward Amyloid-β Binds to a Unique Epitope within the N-Terminal Region. Antibodies 2024, 13, 68.

11. Cost-Effective Method for Full-Length Sequencing of Monoclonal Antibodies from Hybridoma Cells

对杂交瘤细胞单克隆抗体进行全长测序的经济有效的方法

https://www.mdpi.com/2073-4468/14/3/72

Döring, S.; Tscheuschner, G.; Flemig, S.; Weller, M.G.; Konthur, Z. Cost-Effective Method for Full-Length Sequencing of Monoclonal Antibodies from Hybridoma Cells. Antibodies 2025, 14, 72.

12. Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence

扁平苔藓的单克隆抗体和小分子疗法：靶向免疫调节和新兴证据

https://www.mdpi.com/2073-4468/14/3/79

Rosset, F.; Sciamarrelli, N.; Mastorino, L.; Pala, V.; Boskovic, S.; Bongiovanni, E.; Crespi, O.; Liao, Y.; Ribero, S.; Quaglino, P. Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence. Antibodies 2025, 14, 79.

13. Impact of Light-Chain Variants on the Expression of Therapeutic Monoclonal Antibodies in HEK293 and CHO Cells

轻链变体对HEK293和CHO细胞中治疗性单克隆抗体表达的影响

https://www.mdpi.com/2073-4468/14/3/53

Veber, A.; Lenau, D.; Gkragkopoulou, P.; Kornblüh Bauer, D.; Focken, I.; Leuschner, W.D.; Beil, C.; Weil, S.; Rao, E.; Langer, T. Impact of Light-Chain Variants on the Expression of Therapeutic Monoclonal Antibodies in HEK293 and CHO Cells. Antibodies 2025, 14, 53.

14. Diversity in the HLA-I Recognition of HLA-F Monoclonal Antibodies: HLA-F or HLA-Ib Monospecific, HLA-E or HLA-G Bispecific Antibodies with or without HLA-Ia Reactivity

HLA-F 单克隆抗体对 HLA-I 识别的多样性：HLA-F 或 HLA-Ib 单特异性抗体，具有或不具有 HLA-Ia 反应性的 HLA-E 或 HLA-G 双特异性抗体

https://www.mdpi.com/2073-4468/13/1/8

Ravindranath, M.H.; Ravindranath, N.M.; Amato-Menker, C.J.; El Hilali, F.; Filippone, E.J. Diversity in the HLA-I Recognition of HLA-F Monoclonal Antibodies: HLA-F or HLA-Ib Monospecific, HLA-E or HLA-G Bispecific Antibodies with or without HLA-Ia Reactivity. Antibodies 2024, 13, 8.

15. The Role of Monoclonal Antibodies as Therapeutics in HPV-Related Head and Neck Cancers: An Updated Review

单克隆抗体在HPV相关头颈癌治疗中的作用：最新综述

https://www.mdpi.com/2073-4468/14/2/37

Zalin, M.; Patel, S.; Coggins, C.; Rai, V. The Role of Monoclonal Antibodies as Therapeutics in HPV-Related Head and Neck Cancers: An Updated Review. Antibodies 2025, 14, 37.